Claims for Patent: 5,965,525

Summary for Patent: 5,965,525

Title:	Cyclic peptide antifungal agents
Abstract:	Provided are compounds of the formula (1): ##STR1## wherein R' is hydrogen, methyl or NH2 C(O)CH2 --;R" and R'" are independently methyl or hydrogen;R and Ry are independently hydroxy or hydrogen;R1 is hydroxy, hydrogen, or hydroxysulfonyloxy;R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy;R2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
Inventor(s):	Frederick J. Burkhardt, Manuel Debono, Jeffrey S. Nissen, William W. Turner, Jr.
Assignee:	Eli Lilly and Co
Application Number:	US08/449,056
Patent Claims:	1. A compound of the formula ( 1): ##STR251## wherein R' is hydrogen, methyl or NH2 C(O)CH2 --;R" and R'" are independently methyl or hydrogen; R and Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, or hydroxysulfonyloxy; and R2 is an acyl group represented by the formula ##STR252## wherein: Z is --O--, --C.tbd.C--, --CH═CH--, --CH2 --CH2 --, --CH2 --, or a carbon to carbon bond; A) R4 is hydrogen, C2 -C12 alkynyl, C2 -C12 substituted alkynyl, C3 -C12 cycloalkyl, C7 -C10 bicycloalkyl, C7 -C14 tricycloalkyl, C1 -C12 alkoxy, C3 -C12 cycloalkoxy, naphthyl, pyridyl, thienyl, benzothienyl, quinolyl or phenyl; or B) R4 is phenyl substituted by amino, C1 -C12 alkylthio, halogen, C1 -C12 alkyl, C2 -C12 alkenyl, C2 -C12 alkynyl, C1 -C12 substituted alkyl, C2 -C12 substituted alkenyl, C2 -C12 substituted alkynyl, C1 -C12 alkoxy, trifluoromethyl, phenyl, substituted phenyl, phenyl substituted with a polyoxa-alkyl group represented by the formula --O--(CH.sub.2).sub.m --[O--(CH.sub.2).sub.n ].sub.p --O--(C.sub.1 -C.sub.12 alkyl) wherein m and n are integers of from 2 to 4, and p is 0 or 1; or C) R4 is phenyl substituted with C1 -C6 alkoxy substituted by fluoro, bromo, chloro or iodo; or D) R4 is C1 -C12 alkoxy substituted with C3 -C12 cycloalkyl, C7 -C12 bicycloalkyl, C7 -C14 tricycloalkyl, C2 -C12 alkynyl, amino, C1 -C4 alkylamino, di-(C1 -C4 alkyl)amino, C1 -C12 alkanoylamino, phenyl substituted with a polyoxa-alkyl group represented by the formula --O--(CH.sub.2).sub.m --[O--(CH.sub.2).sub.n ].sub.p --O--(C.sub.1 -C.sub.12 alkyl) wherein m, n and p are as defined above; or E) R4 is C1 -C12 alkoxy substituted with a group of the formula ##STR253## wherein R8 is C1 -C6 alkoxy optionally substituted with phenyl; or F) R4 is a group represented by the formula --O--(CH.sub.2).sub.p' --W--R.sub.5 wherein p' is an integer of from 2 to 4; W is pyrrolidino, piperidino or piperazino, and R5 is hydrogen, C1 -C12 alkyl, C3 -C12 cycloalkyl, benzyl or C3 -C12 cycloalkylmethyl; or G) R4 is a group represented by the formula --Y--R.sub.6 wherein Y is --C.tbd.C-- or --CH═CH--; and R6 is C1 -C12 alkyl, C1 -C12 substituted alkyl; C3 -C12 cycloalkyl, C7 -C10 bicycloalkyl, C7 -C14 tricycloalkyl, phenyl, C3 -C12 cycloalkenyl, naphthyl, benzothiazolyl, thienyl, indanyl, fluorenyl, phenyl substituted by amino, C1 -C12 alkylthio, halogen, C1 -C12 alkyl, C2 -C12 alkenyl, C2 -C12 alkynyl, C1 -C12 alkoxy, trifluoromethyl, --O--(CH2)p' --W--R5, or C1 -C6 alkoxy substituted by fluoro, bromo, iodo or chloro; or R6 is phenyl substituted by a polyoxa-alkyl group represented by the formula --O--(CH.sub.2).sub.m --[O--CH.sub.2).sub.n ].sub.p --O--(C.sub.1 -C.sub.12 alkyl) wherein m, n and p are as defined above; or a pharmaceutically acceptable salt thereof; with the proviso that when R' is methyl or NH2 C(O)CH2 --; R" is methyl; R'" is methyl; Ry is hydroxy; andeither a) or b) a) R1 is hydroxysulfonyloxy and R7 is hydroxy, or hydroxysulfonyloxy; b) R1 is hydrogen or hydroxysulfonyloxy and R7 is hydroxysulfonyloxy; R2 is not ##STR254## wherein Z is a carbon to carbon bond or --O-- and R4 is hydrogen or C1 -C12 alkoxy. 2. A compound as recited in claim 1 where R2 is an acyl group represented by the formula ##STR255## wherein Z is --O--, --C.tbd.C--, --CH═CH--, --CH2 --CH2 --, --CH2 --, or a carbon to carbon bond;R4 is phenyl or phenyl substituted by amino, C1 -C12 alkylthio, halogen, C1 -C12 alkyl, C2 -C12 alkenyl, C2 -C12 alkynyl, C1 -C12 substituted alkyl, C2 -C12 substituted alkenyl, C2 -C12 substituted alkynyl, C1-C12 alkoxy; trifluoromethyl, phenyl, substituted phenyl, phenyl substituted with a polyoxa-alkyl group represented by the formula --O--(CH.sub.2).sub.m --[O--(CH.sub.2).sub.n ].sub.p --O--(C.sub.1 -C.sub.12 alkyl) wherein m and n are integers of from 2 to 4, and p is 0 or 1; or R4 is phenyl substituted with C1 -C6 alkoxy substituted by fluoro, bromo, chloro or iodo; or R4 is a group represented by the formula --O--(CH.sub.2).sub.p' --W--R.sub.5 wherein p' is an integer of from 2 to 4; W is pyrrolidino, piperidino or piperazino, and R5 is hydrogen, C1 -C12 alkyl, C3 -C12 cycloalkyl, benzyl or C3 -C12 cycloalkylmethyl; or R4 is a group represented by the formula --Y--R.sub.6 wherein Y is --C.tbd.C-- or --CH═CH--; and R6 is C1 -C12 alkyl, C1 -C12 substituted alkyl, C3 -C12 cycloalkyl, C7 -C10 bicycloalkyl, C7 -C14 tricycloalkyl, phenyl, C3 -C12 cycloalkenyl, naphthyl, benzothiazolyl, thienyl, indanyl, fluorenyl, phenyl substituted by amino, C1 -C12 alkylthio, halogen, C1 -C12 alkyl, C2 -C12 alkenyl, C2 -C12 alkynyl, C1 -C12 alkoxy, trifluoromethyl, --O--(CH2)p' --W--R5, or C1 -C6 alkoxy substituted by fluoro, bromo, iodo or chloro; or R6 is phenyl substituted by a polyoxa-alkyl group represented by the formula --O--(CH.sub.2).sub.m --[O--CH.sub.2).sub.n ].sub.p --O--(C.sub.1 -C.sub.12 alkyl) wherein m, n and p are as defined above; or a pharmaceutically acceptable salt thereof. 3. The compound as recited in claim 2 wherein R2 is of the formula ##STR256## wherein Z is --C.tbd.C--; andR4 is phenyl substituted by C1 -C12 alkoxy or phenyl substituted with a polyoxa-alkyl group of the formula --O--(CH.sub.2).sub.m --[O--(CH.sub.2).sub.n ].sub.p --O--(C.sub.1 -C.sub.12 alkyl). 4. The compound as recited in claim 2 wherein R2 is of the formula ##STR257## wherein Z is a carbon to carbon bond and R4 is a group of the formula --O--(CH.sub.2).sub.p' --W--R.sub.5 wherein W is a piperidino group. 5. The compound as recited in claim 4 wherein p' is 2. 6. The compound as recited in claim 5 wherein R5 is hydrogen, n-propyl, 4-benzyl, 4-cyclohexyl, or 4-cyclohexylmethyl. 7. The compound as recited in claim 1 wherein R', R" and R'" are methyl, R1 is hydrogen, and R7 and Ry are OH. 8. The compound as recited in claim 1 wherein R2 is of the formula ##STR258## wherein Z is a carbon to carbon bond; andR4 is C3 -C7 cycloalkoxy, C1 -C6 alkoxy substituted by C3 -C7 cycloalkyl; or R4 is phenyl substituted by C1 -C12 alkoxy or phenyl substituted with a polyoxa-alkyl group of the formula --O--(CH.sub.2).sub.m --[O--(CH.sub.2).sub.n ].sub.p --O--(C.sub.1 -C.sub.12 alkyl) R4 is a group of the formula --Y--R6, wherein Y is an acetylenic bond and R6 is C1 -C6 alkyl, phenyl, or phenyl substituted with a polyoxa-alkyl group of the formula --O--(CH.sub.2).sub.m --[O--(CH.sub.2)n].sub.p --O--(C.sub.1 -C.sub.12 alkyl). 9. The compound as recited in claim 1, wherein R is hydrogen. 10. The compound as recited in claim 1 wherein R2 is of the formula ##STR259## 11. A method for inhibiting parasitic activity comprising contacting a compound of claim 1 with a parasite. 12. A method for inhibiting fungal activity comprising contacting a compound of claim 1 with a fungus. 13. A method for inhibiting the growth of organisms responsible for opportunistic infections in immunosuppressed individuals comprising administering a compound of claim 1 to said individual. 14. A method for inhibiting the growth of Pneumocystis carinii comprising contacting a compound of claim 1 with Pneumocystis carinii. 15. A pharmaceutical formulation comprising a compound of claim 1 and a suitable pharmaceutical carrier. 16. A compound of the formula (1): whereinR' is hydrogen, methyl or NH2 C(O)CH2 --; R" and R'" are independently methyl or hydrogen; R and Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, or hydroxysulfonyloxy; and I) R2 is a group of the formula ##STR260## and pharmaceutically acceptable salts thereof. 17. The compound as recited in claim 16 wherein R', R" and R'" are methyl, R1 is hydrogen, R7 and Ry are hydroxy, and R is hydroxy. 18. A method for inhibiting parasitic activity comprising contacting a compound of claim 16 with a parasite. 19. A method for inhibiting fungal activity comprising contacting a compound of claim 16 with a fungus. 20. A method for inhibiting the growth of organisms responsible for opportunistic infections in immunosuppressed individuals comprising administering a compound of claim 16 to said individual. 21. A method for inhibiting the growth of Pneumocystis carinii comprising contacting a compound of claim 16 with said Pneumocystis carinii. 22. A pharmaceutical formulation comprising a compound of claim 16 and a suitable pharmaceutical carrier. 23. A compound of the formula ##STR261##